A Stanford University spinout is joining the small army of biotech companies trying to find drugs for amyotrophic lateral sclerosis (ALS).
Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology Approach to Treating Neurodegenerative and Aging-related Diseases
Tranquis Therapeutics are committed to the discovery and development of innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases.
The companies will evaluate novel formulations of drugs that have been notoriously difficult to formulate and deliver into the skin.
BioWorld: Drug developers’ Golden Ticket, worth a lot more than a tour of a candy manufacturing plant
Bacchus Therapeutics and PTM Therapeutics have each won a 2020 AbbVie Golden Ticket at MBC BioLabs.
Read online article at BUSINESS WIRE San Francisco, Calif., April 21, 2020 /BUSINESS WIRE -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a [...]
AMGEN is accepting submissions for the Golden Ticket through June 24, 2020